Cardiff Oncology Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except par value)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $18,658 | $21,655 |
| Short-term investments | 48,529 | 53,168 |
| Accounts receivable and unbilled receivable | 393 | 288 |
| Prepaid expenses and other current assets | 2,410 | 2,301 |
| Total current assets | 69,990 | 77,412 |
| Property and equipment, net | 1,199 | 1,238 |
| Operating lease right-of-use assets | 1,574 | 1,708 |
| Other assets | 1,275 | 1,279 |
| Total Assets | $74,038 | $81,637 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,191 | $1,966 |
| Accrued liabilities | 5,956 | 7,783 |
| Operating lease liabilities | 696 | 691 |
| Total current liabilities | 11,843 | 10,440 |
| Operating lease liabilities, net of current portion | 1,301 | 1,458 |
| Total Liabilities | 13,144 | 11,898 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Preferred stock, 20,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at March 31, 2024 and December 31, 2023 with liquidation preference of $1,074 and $1,068 at March 31, 2024 and December 31, 2023, respectively (Note 5) | — | — |
| Common stock, $0.0001 par value, 150,000 shares authorized; 44,710 and 44,677 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 4 | 4 |
| Additional paid-in capital | 409,781 | 409,343 |
| Accumulated other comprehensive loss | (132) | (67) |
| Accumulated deficit | (348,759) | (339,541) |
| Total stockholders’ equity | 60,894 | 69,739 |
| Total liabilities and stockholders’ equity | $74,038 | $81,637 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.